Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

ACC.23 Together With WCC – Integrating Complex Data into Clinical Practice

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    In this program, expert faculty discuss data presented at the 2023 ACC Congress in a concise, informative, on-demand format. This format extends the congress analysis to a broader audience with greater detail than what is available in abstracts. Rapid advances from the meeting require well-planned educational programming to bridge knowledge, competence, and performance gaps.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including clinical cardiologists and interventional cardiologists, as well as critical care, emergency medicine, hospital medicine, interventional radiology, vascular surgeons, vascular medicine specialists, and primary care physicians. It will also include nurses, nurse practitioners, physician assistants, pharmacists, and any HCPs involved in the care and/or treatment of cardiovascular patients.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Evaluate recent practice-changing data that can be applied to practice and patients
    • Apply recently presented data into clinical practice to expand treatment options and improve patient outcomes
    • Discuss new data on novel agents and therapeutic approaches for patients with application in the community setting
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Marius Hoeper, MD, faculty for this educational event, receives consulting fees from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GSK, Janssen, and MSD. 

    Steven Nissen, MD, MACC, faculty for this educational event, receives research funds from Abbvie, AstraZeneca, Amgen, Bristol Myers Squibb, Eli Lilly, Esperion, Medtronic, MyoKardia, New Amsterdam Pharmaceuticals, Novartis, Pfizer, and Silence Therapeutics.

    Kelly Chin, MD, faculty for this educational event, receives research funds from Acceleron, Altavant, Gossamer Bio, Janssen, Merck, Pfizer and United Therapeutics; and receives consulting fees from Arena, Acceleron and Shouti. 

    Christie Mitchell Ballantyne, MD, faculty for this educational event, receives research funds from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, and Roche Diagnostic; and receives consulting fees from 89Bio, Abbott Diagnostics, Alnylam

    Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas, BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, and Roche Diagnostic.

    R. Kevin Rogers, MD, MSc, RPVI, faculty for this educational event, has no relevant financial relationships with ineligible companies.

    Marc P. Bonaca, MD, MPH, FAHA, FACC, faculty for this educational event, receives research funds from Abbott Laboratories, Adamis Pharmaceuticals Corporation, Agios Pharmaceuticals, Inc., Alexion Pharma, Alnylam Pharmaceuticals, Inc., Amgen Inc., Angionetics, Inc., ARCA Biopharma, Inc., Array BioPharma, Inc., AstraZeneca and Affiliates, Atentiv LLC, Audentes Therapeutics, Inc., Bayer and Affiliates, Beth Israel Deaconess Medical Center, Better Therapeutics, Inc., BIDMC, Boston Clinical Research Institute, Bristol-Meyers Squibb Company, Cambrian Biopharma, Inc., Cardiol Therapeutics Inc., CellResearch Corp., Cook Medical Incorporated, Covance, CSL Behring LLC, Eidos Therapeutics, Inc., EP Trading Co. Ltd., EPG Communication Holdings Ltd., Epizon Pharma, Inc., Esperion Therapeutics, Inc., Everly Well, Inc., Exicon Consulting Pvt. Ltd., Faraday Pharmaceuticals, Inc., Foresee Pharmaceuticals Co. Ltd., Fortress Biotech, Inc., HDL Therapeutics Inc., HeartFlow Inc., Hummingbird Bioscience, Insmed Inc., Ionis Pharmaceuticals, IQVIA Inc., JanOne Biotech Holdings Inc., Janssen and Affiliates, Kaneka, Kowa Research Institute, Inc., Kyushu University, Lexicon Pharmaceuticals, Inc., LSG Kyushu University, Medimmune Ltd., Medpace, Merck & Affiliates, Novartis Pharmaceuticals Corp., Novate Medical, Ltd., Novo Nordisk, Inc., Pan Industry Group, Pfizer Inc., PhaseBio Pharmaceuticals, Inc., PPD Development, LP, Prairie Education and Research Cooperative, Prothena Biosciences Limited, Regeneron Pharmaceuticals, Inc., Regio Biosciences, Inc., Rexgenero, Sanifit Therapeutics S.A., Sanofi-Aventis Groupe, Silence Therapeutics PLC, Smith & Nephew plc, Stealth BioTherapeutics Inc., State of Colorado CCPD Grant, The Brigham & Women's Hospital, Inc., The Feinstein Institutes for Medical Research, Thrombosis Research Institute, University of Colorado, University of Pittsburgh, VarmX, Virta HealthCorporation, WCT Atlas, Worldwide Clinical Trials Inc., WraSer, LLC,Yale Cardiovascular Research Group, and AHA SFRN; receives consulting fees from Audentes; and has an ownership interest in Medtronic and Pfizer.

    Marat Fudim, MD, MHS, faculty for this educational event, receives consulting fees from Merck.

    Cynthia M. Westerhout, PhD, faculty for this educational event, receives consulting fees from Bayer Canada.

    Stephen J. Greene, MD, FACC, FHFSA, faculty for this educational event, receives research funds from AstraZeneca, Amgen, Cytokinetics, Pfizer, Merck, Novartis, Sanofi, Bristol Myers Squibb; and receives consulting fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Cytokineteics, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, Urovant Pharmaceuticals, CSL Vifor and scPharmaceuticals. 

    Ahmad Masri, MD, MS, faculty for this educational event, receives research funds from Pfizer, Ionis/Akcea, Attralus, Cytokinetics, Ultromics and the Wheeler Foundation; and receives consulting fees from Cytokinetics, BMS, Eidos, Pfizer, Ionis, Lexicon, Alnylam, Attralus, Haya, Intellia and Tenaya.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Prerna Poojary, PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp and Cytokinetics, Incorporated.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statements

    This activity is FREE to all participants.


  • Instructions for Completion

    During the period 3/27/2023 through 3/27/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Mar 2024